The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.
SUBSTRATE REDUCTION THERAPY
申请人:Platt Mary Frances
公开号:US20100204162A1
公开(公告)日:2010-08-12
The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
[EN] EPITOPE REDUCTION THERAPY<br/>[FR] THÉRAPIE PAR RÉDUCTION D'ÉPITOPES
申请人:ISIS INNOVATION
公开号:WO2008012555A2
公开(公告)日:2008-01-31
[EN] The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease. [FR] Cette invention concerne l'emploi dune inhibiteur de la biosynthèse de glycolipides pour la fabrication d'un médicament destiné au traitement de maladies autoimmunes à médiation glycolipidique.
[EN] SUBSTRATE REDUCTION THERAPY<br/>[FR] THÉRAPIE PAR RÉDUCTION DE SUBSTRAT
申请人:ISIS INNOVATION
公开号:WO2009001097A2
公开(公告)日:2008-12-31
[EN] The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. [FR] La présente invention concerne un composé qui est un inhibiteur de la biosynthèse de sphingolipides, à utiliser pour le traitement d'une maladie présentant une phénotype cellulaire secondaire de type maladie de Niemann-Pick de type C.